Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06777485

China Liver Cancer Clinical Registry Cohort Database (HEAL)

This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Liver Cancer Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Anqing First People's Hospital, Anqing, Anhui, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years, no gender limit
  • Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
  • Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples

Exclusion criteria

  • Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
  • Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
  • Pregnant or breastfeeding women
  • Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected

Treatment and study plan

Procedure/Surgery treatment

Procedure

Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC

Anti-Tumor Drugs

Drug

Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs

Primary outcomes

  1. OS

    Time frame: 10 years

    Time from enrollment to first recorded occurrence of death from any cause

Secondary outcomes

  1. RFS

    Time frame: 10 years

    Time from enrollment to the first documented occurrence of local, regional, or metastatic liver cancer or death from any cause, whichever occurs first.

  2. Survival time after recurrence

    Time frame: 10 years

    The time from the first documented occurrence of localized, regional, or metastatic liver cancer, whichever occurs first, to death from any cause.

Study contacts

Contact information is provided by the study sponsor or research team.

Ji-Zhou Wang, MD PhD

CONTACT

[email protected]

+86 13836135864

Lianxin Liu, MD PhD

CONTACT

[email protected]

+86 13845159888

Sponsors and collaborators

Lead sponsor

Anhui Provincial Hospital

Other Gov

Registry information

Important dates

Study start
2025
Primary completion
2035
Study completion
2035
First posted
Jan 15, 2025
Registry last updated
Aug 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.